- Cannabinoid-drug developer, Tetra Bio-Pharma (TSXV:TBP) has received approval from Health Canada to recommence a veterinary clinical study
- The study will investigate how effectively the company’s ophthalmic drug treats indolent corneal ulcers in companion animals and pets
- The study had to halt in April, when new COVID-19 regulations stopped participants from bringing their pets to the clinic
- Health Canada’s Veterinary Drugs Directorate has renewed the trial, with treatment beginning as soon as clinics reopen to the public
- Tetra Bio-Pharma (TBP) is up 1.52 per cent, with shares trading for C$0.34 and a $82.1 million market cap
Cannabinoid-drug developer, Tetra Bio-Pharma (TSXV:TBP) has received approval from Health Canada to recommence a veterinary clinical study.
The study will investigate the efficacy of the company’s ophthalmic drug in the treatment of indolent corneal ulcers. The trial is focusing on companion animals and pets.
The trial previously had to halt, due to concerns surround the COVID-19 pandemic. New restrictions hindered participants from bringing their pets to the treatment centre. As a result, enrolment was difficult, and the company postponed the study in April.
However, with new case numbers in Canada beginning to slow, Health Canada’s Veterinary Drugs Directorate has renewed the trial. The renewal has extended the maximum length of the trial by another year.
By the time the study had to halt, half of the participants had already completed the trial’s treatment and follow-up phase. None had shown any adverse side effects from the drug.
The remaining participant will start the trial as soon as veterinary clinics reopen to the public.
Tetra Bio-Pharma’s CRO and CEO, Guy Chamberland, was pleased the trial can now safely continue.
“As a health care corporation, Tetra fully supports the measures taken by governments to protect its citizens.
“These measures had only a minor impact on the ophthalmic operations compared to the significant public health benefit. We are glad that the participants and support staff involved in the trial are healthy and safe and that we can now initiate re-activation of the trial,” he said.
Tetra Bio-Pharma (TBP) is up 1.52 per cent, with shares trading for C$0.34 at 11:52am EDT.
